Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alcobra Ltd announces FDA clearance of IND for Metadoxine extended release


Thursday, 6 Mar 2014 09:15am EST 

Alcobra Ltd:Says the US. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MDX.This step will allow for the initiation of US clinical trials.Unlike the most commonly prescribed ADHD medications, MDX is not a stimulant.MDX has a mechanism of action that neither targets dopamine nor norepinephrine. 

Company Quote

3.93
-0.07 -1.75%
26 Dec 2014